SAO PAULO (Reuters) -Novo Nordisk, the producer of Ozempic and other medications, announced on Monday a 6.4 billion reais ($1.09 billion) investment in Brazil to boost production.
The investment aims to increase the manufacturing capacity at Novo Nordisk’s facility in Minas Gerais state of injectable drugs for the treatment of obesity, diabetes, and other serious chronic diseases, the company said in a statement.
($1 = 5.8721 reais)
(Reporting by Paula Arend Laier; Writing by Isabel Teles; Editing by Anthony Esposito)
Comments